# US 9,750,774 B2 · Strain for the treatment and/or prevention of chronic inflammatory diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,750,774 B2
- Document ID: US9750774B2
- Status: Granted
- Kind: B2
- Application number: 14/901,154
- Filed: 2014-06-24
- Published: 2016-05-19
- Granted: 2017-09-05
- Earliest claimed: 2013-06-28
- Assignees: Lesaffre Et Compagnie; Ecole Nationale Superieure Des Sciences Agronomiques De Bordeaux Aquitaine (Borde Aux Sciences Agro)
- Applicants: Lesaffre Et Compagnie; Ecole Nationale Superieure Des Sciences Agronomiques De Bordeaux Aquitaine (Bordeaux Sciences Agro)
- Inventors: Patrick Taillade; Maria Urdaci
- Web page: https://patentgrep.com/patent/US9750774B2

## CPC

- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns the probiotic strain Bacillus subtilis CU1 filed with the French Collection Nationale de Culture des Microorganismes (National Collection of Microorganism Cultures) under number I-2745, cells obtained by culturing said strain and a composition comprising cells obtained by culturing said strain, for the use thereof in the treatment and/or prevention of chronic inflammatory diseases, and in particular chronic inflammatory rheumatism.

## Claims

### Claim 1

A method for treating a chronic inflammatory diseases in a patient or for delaying an inflammatory flare-up in a chronic inflammatory rheumatism patient, the method comprising administering to the patient an effective amount of Bacillus subtilis strain CU1 filed with the CNCM under number I-2745 on Oct. 25, 2001, to the exclusion of any other strain of bacterium.

### Claim 2 (depends on 1)

The method for as claimed in claim 1, wherein the chronic inflammatory disease is chronic inflammatory rheumatism.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein the chronic inflammatory rheumatism is rheumatoid arthritis.

### Claim 4

A method for treating a chronic inflammatory diseases in a patient or for delaying an inflammatory flare-up in a chronic inflammatory rheumatism patient, the method comprising administering to the patient an effective amount of cells obtained by culturing the Bacillus subtilis strain CU1 filed with the CNCM under number I-2745 on Oct. 25, 2001, to the exclusion of any other strain of bacterium.

### Claim 5 (depends on 4)

The method as claimed in claim 4, wherein the chronic inflammatory disease is chronic inflammatory rheumatism.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the chronic inflammatory rheumatism is rheumatoid arthritis.

### Claim 7 (depends on 4)

The method as claimed in claim 4, wherein the cells are in sporulated form or vegetative form.

### Claim 8 (depends on 4)

The method as claimed in claim 4, wherein the cells are in dry form.

### Claim 9

A method for treating a chronic inflammatory diseases in a patient or for delaying an inflammatory flare-up in a chronic inflammatory rheumatism patient, the method comprising administering to the patient an effective amount of a composition comprising cells obtained by culturing the Bacillus subtilis strain CU1 filed with the CNCM under number I-2745 on Oct. 25, 2001, to the exclusion of any other strain of bacterium.

### Claim 10 (depends on 9)

The method as claimed in claim 9, wherein the chronic inflammatory disease is chronic inflammatory rheumatism.

### Claim 11 (depends on 10)

The method as claimed in claim 10, wherein the chronic inflammatory rheumatism is rheumatoid arthritis.

### Claim 12 (depends on 9)

The method as claimed in claim 9, wherein the cells are in sporulated form or vegetative form.

### Claim 13 (depends on 9)

The method as claimed in claim 9, wherein the cells are in dry form.

### Claim 14 (depends on 9)

The method as claimed in claim 9, wherein the composition is a food composition, a dietary supplement or a pharmaceutical composition.

### Claim 15 (depends on 9)

The method as claimed in claim 9, wherein the composition is orally or topically administered to the patient.

### Claim 16 (depends on 9)

The method as claimed in claim 9, wherein the composition is in the form of capsule, pill, lozenge, tablet, soft capsule, powder, suspension, liquid solution, granule, gel or cream.

### Claim 17 (depends on 9)

The method as claimed in claim 9, wherein the composition further comprises another active ingredient.